5PSQ-036 STOPP/START criteria in patients with HIV

Abstract

antiretroviral treatment or switched to dual therapy based on lamivudine and dolutegravir between June 2018 and September 2019 were included. Study variables were age, sex, date and reason for the change, duration of treatment, viral load (CV, copies/mL), CD4 and CD8 cells (cells/mL) before and after the change and on the date of the last available analysis, previous therapy, glomerular filtration rate (GFR) (mL/min), and levels of cholesterol (mg/dL), low density lipoprotein (LDL, mg/dL) and triglycerides (mg/dL). Results Nine patients (66.66% men) with a mean age of 49 years (30-58), 3 of whom were naive patients (33.33%) were analysed. Effectiveness was 100% of patients who achieved CV <50 copies at 4-6 weeks, maintaining the virological response for an average of 26 weeks. CD4 and CD8 counts increased significantly from 690 to 805 and 910 to 943, respectively. The lipid profile showed differences in LDL from 170 to 120. A significant decrease in GFR was observed from 102 to 87. The annual cost saw a decrease of 1690C ¼ /patient/ year. Conclusion and relevance Simplification to dual therapy was a safe and effective option that allowed optimisation of the resources against triple therapy.

Potentially Inappropriate Prescribing in Older People Living With HIV: A Scoping Review

“…1). Most studies were single centre 22,29,31–33,39–42,44,45,48–52,54,57,59–66 and conducted in Europe. 13,19,28,30–33,39,41,43–51,53,56–63,65,67 The sample size ranged from 2 to 1292 participants, and the population was majority male.…”

“…Most studies were single centre 22,29,31–33,39–42,44,45,48–52,54,57,59–66 and conducted in Europe. 13,19,28,30–33,39,41,43–51,53,56–63,65,67 The sample size ranged from 2 to 1292 participants, and the population was majority male. Twenty-eight studies were cross-sectional, 19,27,28,30–33,39–41,44,45,47–51,53,55,56,61–67 3 were prospective cohort studies, 43,46,57 3 were prospective intervention studies with no control group, 22,59,60 2 nonrandomized controlled studies, 42,52 and 1 randomized controlled study, 58 1 case–control study, 29 and 1 case-report.…”

“…13,19,28,30–33,39,41,43–51,53,56–63,65,67 The sample size ranged from 2 to 1292 participants, and the population was majority male. Twenty-eight studies were cross-sectional, 19,27,28,30–33,39–41,44,45,47–51,53,55,56,61–67 3 were prospective cohort studies, 43,46,57 3 were prospective intervention studies with no control group, 22,59,60 2 nonrandomized controlled studies, 42,52 and 1 randomized controlled study, 58 1 case–control study, 29 and 1 case-report. 54 In most studies, investigators used explicit criteria (Table 1), and in others, implicit criteria or a combination of both (Table 2).…”

“…PRISMA diagram of flow of studies. A total of 39 studies met the inclusion criteria 11,13,19,22,27–33,39–67 reported in 50 articles.…”

“…Those related to untreated musculoskeletal conditions were the most frequently identified in our review and were identified by authors who used the STOPP-START criteria. 47,53,63 Recent observational evidence has found that HIV infection is associated with a twofold increased risk of fractures among men aged 50–59 years compared with men without HIV. 96 ART and other proven risk factors for osteoporotic fractures among PLHIV include older age and white ethnicity, and other established osteoporosis risk factors (eg, low body mass index, smoking, alcohol use, and poor nutrition), which are also more common in PLHIV.…”